7.95
price down icon3.99%   -0.33
after-market Dopo l'orario di chiusura: 7.95
loading
Precedente Chiudi:
$8.28
Aprire:
$8.11
Volume 24 ore:
1.60M
Relative Volume:
0.91
Capitalizzazione di mercato:
$482.66M
Reddito:
$91.06M
Utile/perdita netta:
$-503.14M
Rapporto P/E:
-0.9476
EPS:
-8.39
Flusso di cassa netto:
$-424.74M
1 W Prestazione:
-3.17%
1M Prestazione:
+8.90%
6M Prestazione:
+10.11%
1 anno Prestazione:
-57.58%
Intervallo 1D:
Value
$7.89
$8.11
Intervallo di 1 settimana:
Value
$7.89
$8.81
Portata 52W:
Value
$4.62
$18.76

Sage Therapeutics Inc Stock (SAGE) Company Profile

Name
Nome
Sage Therapeutics Inc
Name
Telefono
617-299-8380
Name
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Name
Dipendente
487
Name
Cinguettio
@SageBiotech
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
SAGE's Discussions on Twitter

Confronta SAGE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SAGE
Sage Therapeutics Inc
7.95 482.66M 91.06M -503.14M -424.74M -8.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-11 Ripresa BofA Securities Underperform
2024-11-21 Aggiornamento RBC Capital Mkts Underperform → Sector Perform
2024-10-10 Ripresa Raymond James Mkt Perform
2024-10-04 Downgrade RBC Capital Mkts Outperform → Sector Perform
2024-07-30 Downgrade TD Cowen Buy → Hold
2024-07-25 Downgrade JP Morgan Overweight → Neutral
2024-05-29 Iniziato Citigroup Sell
2024-05-29 Iniziato Robert W. Baird Neutral
2024-04-17 Downgrade BofA Securities Neutral → Underperform
2023-12-12 Iniziato Deutsche Bank Hold
2023-08-08 Downgrade Canaccord Genuity Buy → Hold
2023-08-08 Downgrade Goldman Buy → Neutral
2023-08-08 Downgrade Needham Buy → Hold
2023-08-07 Downgrade BofA Securities Buy → Neutral
2023-08-07 Downgrade Oppenheimer Outperform → Perform
2023-08-07 Downgrade RBC Capital Mkts Outperform → Sector Perform
2023-08-07 Downgrade Stifel Buy → Hold
2023-08-07 Downgrade Wedbush Outperform → Neutral
2023-07-27 Iniziato Scotiabank Sector Outperform
2023-03-13 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-01-03 Downgrade Guggenheim Buy → Neutral
2022-11-01 Iniziato Loop Capital Hold
2022-03-31 Iniziato Berenberg Hold
2021-11-02 Aggiornamento Guggenheim Neutral → Buy
2021-10-19 Ripresa Morgan Stanley Equal-Weight
2021-10-07 Downgrade Jefferies Buy → Hold
2021-09-23 Iniziato Needham Buy
2021-06-16 Downgrade Citigroup Buy → Neutral
2021-04-07 Iniziato Piper Sandler Overweight
2021-02-26 Downgrade Mizuho Buy → Neutral
2021-02-25 Reiterato H.C. Wainwright Neutral
2021-02-02 Ripresa Raymond James Mkt Perform
2021-01-22 Downgrade BMO Capital Markets Outperform → Market Perform
2021-01-04 Aggiornamento Guggenheim Neutral → Buy
2021-01-04 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-12-04 Aggiornamento Mizuho Neutral → Buy
2020-12-01 Downgrade Raymond James Outperform → Mkt Perform
2020-11-16 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-11-06 Reiterato H.C. Wainwright Neutral
2020-09-11 Aggiornamento Wedbush Neutral → Outperform
2020-08-10 Aggiornamento Raymond James Mkt Perform → Outperform
2020-05-08 Downgrade Wedbush Outperform → Neutral
2020-04-08 Downgrade Guggenheim Buy → Neutral
2020-03-18 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2020-03-06 Iniziato Citigroup Buy
2020-02-28 Reiterato H.C. Wainwright Neutral
2020-02-06 Iniziato Mizuho Neutral
2019-12-06 Reiterato RBC Capital Mkts Outperform
2019-12-05 Reiterato Guggenheim Buy
2019-12-05 Downgrade SunTrust Buy → Hold
2019-10-30 Iniziato H.C. Wainwright Neutral
2019-05-23 Iniziato Wedbush Outperform
2019-04-25 Iniziato Jefferies Buy
2018-12-14 Iniziato Wolfe Research Outperform
2018-10-11 Iniziato Oppenheimer Outperform
Mostra tutto

Sage Therapeutics Inc Borsa (SAGE) Ultime notizie

pulisher
Mar 30, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect - Markets Insider

Mar 30, 2025
pulisher
Mar 29, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

SAGE THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc.SAGE - The Malaysian Reserve

Mar 28, 2025
pulisher
Mar 28, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Rating of “Hold” by Analysts - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - Markets Insider

Mar 27, 2025
pulisher
Mar 27, 2025

Sage Therapeutics ($SAGE) Failed Drug Launch and Misleading FDA Guidance Case - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Status Epilepticus Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Marinus Pharma, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

How To Trade (SAGE) - Stock Traders Daily

Mar 27, 2025
pulisher
Mar 26, 2025

Bank of New York Mellon Corp Has $931,000 Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation - Markets Insider

Mar 25, 2025
pulisher
Mar 22, 2025

Amundi Invests $166,000 in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Mar 22, 2025
pulisher
Mar 19, 2025

Investors who hold shares of Sage Therapeutics, Inc. (NASDAQ: - openPR.com

Mar 19, 2025
pulisher
Mar 18, 2025

US Bancorp DE Acquires 2,268 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

Notice to Long-Term Shareholders of Fluence Energy, Inc. - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc.SAGE - Business Wire

Mar 17, 2025
pulisher
Mar 16, 2025

Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on You - The Globe and Mail

Mar 15, 2025
pulisher
Mar 14, 2025

Notice to Long-Term Shareholders of Mercury Systems, Inc. - GlobeNewswire

Mar 14, 2025
pulisher
Mar 14, 2025

Notice to Long-Term Shareholders of Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims - Morningstar

Mar 14, 2025
pulisher
Mar 14, 2025

Notice to Long-Term Shareholders of Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.

Mar 14, 2025
pulisher
Mar 13, 2025

Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Be - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation - Markets Insider

Mar 13, 2025
pulisher
Mar 13, 2025

Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 13, 2025
pulisher
Mar 12, 2025

Long-Term Shareholder Notice: Driven Brands Holdings, Inc. - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

Sage Therapeutics (NASDAQ:SAGE) Now Covered by Analysts at Bank of America - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Sage Therapeutics stock rated Underperform at BofA (SAGE) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation - Markets Insider

Mar 11, 2025
pulisher
Mar 10, 2025

Sage Therapeutics resumed with an Underperform at BofA - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Attention Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire

Mar 10, 2025
pulisher
Mar 09, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Reach Out - Markets Insider

Mar 09, 2025
pulisher
Mar 07, 2025

SAGE Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld Online

Mar 07, 2025
pulisher
Mar 06, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out - Markets Insider

Mar 06, 2025
pulisher
Mar 05, 2025

Sage’s medical chief is latest leader to leave biotech - The Business Journals

Mar 05, 2025
pulisher
Mar 05, 2025

Sage Therapeutics CMO to leave for new opportunity By Investing.com - Investing.com Canada

Mar 05, 2025
pulisher
Mar 04, 2025

Sage Therapeutics Announces R&D Leadership Transition - citybiz

Mar 04, 2025
pulisher
Mar 04, 2025

Sage Therapeutics announces CMO resignation By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Sage Therapeutics announces CMO resignation - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

SAGE Therapeutics Announces CMO Resignation and Interim Appointment - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

SAGE Therapeutics Announces Research And Development Leadership Transition -March 04, 2025 at 04:49 pm EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Sage Therapeutics CMO to leave for new opportunity - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

SAGE Therapeutics (SAGE) Announces R&D Leadership Transition - StreetInsider.com

Mar 04, 2025
pulisher
Mar 04, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - Markets Insider

Mar 04, 2025
pulisher
Mar 04, 2025

Levi & Korsinsky Notifies Sage Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSAGE - accessnewswire.com

Mar 04, 2025
pulisher
Mar 03, 2025

Levi & Korsinsky Reminds Sage Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

Mar 03, 2025
pulisher
Mar 01, 2025

Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey

Mar 01, 2025
pulisher
Mar 01, 2025

Biogen proposes acquisition of partner Sage Therapeutics - MSN

Mar 01, 2025

Sage Therapeutics Inc Azioni (SAGE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Capitalizzazione:     |  Volume (24 ore):